Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Overcoming Adaptive Resistance to KRASG12D Blockade in Pancreatic Cancer through Vertical Pathway Inhibition.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Jun 2026

Lin Qingxiang, Morales-Giron Alvin A, Sander Conrad, Curtis Jacquelyn M, Barnes Haley, Patel Parasvi S, Fece de la Cruz Ferran, Riedl Jakob M, Matsubara Hiroyuki, Nakamura Hajime, Liss Andrew S, Corcoran Ryan B

Abstract excerpt

PURPOSE: Oncogenic KRAS mutations are present in >90% of pancreatic ductal adenocarcinoma (PDAC), with KRASG12D being the most common. Mutant-selective KRASG12D inhibitors (KRASiG12D) have demonstrated promising initial clinical activity in KRASG12D-mutant PDAC. However, adaptive resistance to KRASi constrains efficacy in some tumor types, such as colorectal cancer, in which EGFR-mediated RAS-MAPK pathway...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Pancreatic Ductal
Share to Cell Line, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to ErbB Receptors

Share to Pancreatic Neoplasms

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins p21(ras)

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 41801133
DOI: 10.1158/1078-0432.CCR-25-1788
PMCID: PMC13223552

Genes

EGFR
KRAS
ERBB3
FGFR1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Overcoming Adaptive Resistance to KRASG12D Blockade in Pancreatic Cancer through Vertical Pathway Inhibition.PMID 41801133Read ↗

KRAS-Dependency in Pancreatic Ductal Adenocarcinoma: Mechanisms of Escaping in Resistance to KRAS Inhibitors and Perspectives of TherapySemantic proximity Read ↗

CRISPR-Cas9 Screening Identifies Resistance Mechanisms to KRAS Inhibition in Pancreatic Cancer.Semantic proximity Read ↗

KRAS-dependency in Pancreatic Ductal Adenocarcinoma: Mechanisms of Escaping in Resistance to KRAS InhibitorsSemantic proximity Read ↗

Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition.Semantic proximity Read ↗

Overcoming Daraxonrasib Resistance: Allele-Specific Mechanisms Guide Salvage Therapy in Pancreatic CancerSemantic proximity Read ↗

Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer.Semantic proximity Read ↗

Targeting AXL Overcomes Adaptive Resistance to KRAS Inhibition in KRAS-Driven CancerSemantic proximity Read ↗

KRAS Pathway-based Therapeutic Approaches in Pancreatic Cancer.Semantic proximity Read ↗

Targeting KRAS mutations in pancreatic cancer: opportunities for future strategiesSemantic proximity Read ↗

Overcoming Adaptive Resistance to KRAS Inhibitors Through Vertical Pathway Targeting.Semantic proximity Read ↗

Distinct clinical outcomes and biological features of specific KRAS mutants in human pancreatic cancer.Semantic proximity Read ↗

Altered PI3K and ERK/MAPK Signaling in KRASG12R-Driven Pancreatic Cancer Presents Opportunities for Precision Therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.